Domestic price of Trastuzumab

Trastuzumab (Trastuzumab) is a humanized recombinant monoclonal antibody targeting the extracellular domain of HER2. The use of trastuzumab is considered the standard treatment for early-stage and metastatic HER2-overexpressing breast cancer. A large number of clinical trials have confirmed that trastuzumab can improve overall survival in metastatic breast cancer. In early breast cancer, when combined with chemotherapy, it improved disease-free survival (DFS) and OS and increased pathological complete response (pCR) in the neoadjuvant setting (66.7% in the trastuzumab arm vs. 25% in the non-chemotherapy arm).

Initial studies of trastuzumab showed that it improved overall survival from 20.3 months to 25.1 months in advanced (metastatic) HER2-positive breast cancer. In early-stage HER2-positive breast cancer, it reduces the risk of the cancer coming back after surgery. The absolute reduction in the risk of cancer recurrence over three years was 9.5%, and the absolute reduction in the risk of death over three years was 3%. However, it increased the absolute risk of serious heart problems by 2.1%, although these problems may resolve if treatment is stopped.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The drug ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult the medical consultant. There is currently no generic drug of trastuzumab on the market.